Propanc Biopharma, Inc. Common Stock (PPCB) - Net Assets
Based on the latest financial reports, Propanc Biopharma, Inc. Common Stock (PPCB) has net assets worth $10.45 Million USD as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($15.11 Million) and total liabilities ($4.66 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Read PPCB current and long-term liabilities for a breakdown of total debt and financial obligations.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $10.45 Million |
| % of Total Assets | 69.17% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
Propanc Biopharma, Inc. Common Stock - Net Assets Trend (2010–2025)
This chart illustrates how Propanc Biopharma, Inc. Common Stock's net assets have evolved over time, based on quarterly financial data. Also explore Propanc Biopharma, Inc. Common Stock balance sheet assets for the complete picture of this company's asset base.
Annual Net Assets for Propanc Biopharma, Inc. Common Stock (2010–2025)
The table below shows the annual net assets of Propanc Biopharma, Inc. Common Stock from 2010 to 2025. For live valuation and market cap data, see Propanc Biopharma, Inc. Common Stock market cap and net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-06-30 | $13.91 Million | +467.98% |
| 2024-06-30 | $-3.78 Million | -21.23% |
| 2023-06-30 | $-3.12 Million | -3.09% |
| 2022-06-30 | $-3.02 Million | +1.43% |
| 2021-06-30 | $-3.07 Million | +15.76% |
| 2020-06-30 | $-3.64 Million | +15.34% |
| 2019-06-30 | $-4.30 Million | +36.30% |
| 2018-06-30 | $-6.75 Million | -24.08% |
| 2017-06-30 | $-5.44 Million | -112.13% |
| 2016-06-30 | $-2.57 Million | +15.99% |
| 2015-06-30 | $-3.05 Million | -116.82% |
| 2014-06-30 | $-1.41 Million | -77.71% |
| 2013-06-30 | $-792.48K | -47.32% |
| 2012-06-30 | $-537.92K | -105.12% |
| 2011-06-30 | $10.51 Million | +5721.80% |
| 2010-06-30 | $-186.90K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Propanc Biopharma, Inc. Common Stock's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 12392715700.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (June 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $11.62K | 0.08% |
| Other Comprehensive Income | $1.32 Million | 9.48% |
| Other Components | $138.20 Million | 993.78% |
| Total Equity | $13.91 Million | 100.00% |
Propanc Biopharma, Inc. Common Stock Competitors by Market Cap
The table below lists competitors of Propanc Biopharma, Inc. Common Stock ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
CCSC Technology International Holdings Limited Ordinary Shares
NASDAQ:CCTG
|
$2.10 Million |
|
Luxbright AB
ST:LXB
|
$2.10 Million |
|
CPT GLOBAL LTD
F:714
|
$2.11 Million |
|
Fluicell AB
ST:FLUI
|
$2.11 Million |
|
AFC Energy plc
LSE:AFC
|
$2.10 Million |
|
Nextferm Technologies Ltd
TA:NXFR
|
$2.09 Million |
|
Iterum Therapeutics PLC
NASDAQ:ITRM
|
$2.09 Million |
|
Constellation Technologies Ltd
AU:CT1
|
$2.09 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Propanc Biopharma, Inc. Common Stock's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from -3,779,059 to 13,906,192, a change of 17,685,251.
- Net loss of 58,923,300 reduced equity.
- Other comprehensive income increased equity by 49,336.
- Other factors increased equity by 76,559,215.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-58.92 Million | -423.72% |
| Other Comprehensive Income | $49.34K | +0.35% |
| Other Changes | $76.56 Million | +550.54% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Propanc Biopharma, Inc. Common Stock's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.03x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2010-06-30 | $-9345150.00 | $0.10 | x |
| 2011-06-30 | $525365450.00 | $0.10 | x |
| 2012-06-30 | $-26895950.00 | $0.10 | x |
| 2013-06-30 | $-39623800.00 | $0.10 | x |
| 2014-06-30 | $-70415700.00 | $0.10 | x |
| 2015-06-30 | $-50891933.33 | $0.10 | x |
| 2016-06-30 | $-16033081.25 | $0.10 | x |
| 2017-06-30 | $-34010943.75 | $0.10 | x |
| 2018-06-30 | $-42199500.00 | $0.10 | x |
| 2019-06-30 | $-4301236.00 | $0.10 | x |
| 2020-06-30 | $-1820712.50 | $0.10 | x |
| 2021-06-30 | $-1022524.33 | $0.10 | x |
| 2022-06-30 | $-1007883.00 | $0.10 | x |
| 2023-06-30 | $-31171.79 | $0.10 | x |
| 2024-06-30 | $-2666.94 | $0.10 | x |
| 2025-06-30 | $3.50 | $0.10 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Propanc Biopharma, Inc. Common Stock utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -423.72%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.41x
- Recent ROE (-423.72%) is below the historical average (-27.76%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2010 | 0.00% | 0.00% | 0.00x | 0.00x | $-823.31K |
| 2011 | -20.48% | 0.00% | 0.00x | 1.03x | $-3.20 Million |
| 2012 | 0.00% | 0.00% | 0.00x | 0.00x | $-11.38 Million |
| 2013 | 0.00% | 0.00% | 0.00x | 0.00x | $-1.36 Million |
| 2014 | 0.00% | 0.00% | 0.00x | 0.00x | $-688.73K |
| 2015 | 0.00% | 0.00% | 0.00x | 0.00x | $-3.11 Million |
| 2016 | 0.00% | 0.00% | 0.00x | 0.00x | $-9.15 Million |
| 2017 | 0.00% | 0.00% | 0.00x | 0.00x | $-7.32 Million |
| 2018 | 0.00% | 0.00% | 0.00x | 0.00x | $-6.36 Million |
| 2019 | 0.00% | 0.00% | 0.00x | 0.00x | $-5.33 Million |
| 2020 | 0.00% | 0.00% | 0.00x | 0.00x | $-4.38 Million |
| 2021 | 0.00% | 0.00% | 0.00x | 0.00x | $-1.72 Million |
| 2022 | 0.00% | 0.00% | 0.00x | 0.00x | $-2.36 Million |
| 2023 | 0.00% | 0.00% | 0.00x | 0.00x | $-2.35 Million |
| 2024 | 0.00% | 0.00% | 0.00x | 0.00x | $-1.44 Million |
| 2025 | -423.72% | 0.00% | 0.00x | 1.41x | $-60.31 Million |
Industry Comparison
This section compares Propanc Biopharma, Inc. Common Stock's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $44,828,400
- Average return on equity (ROE) among peers: -124.18%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Propanc Biopharma, Inc. Common Stock (PPCB) | $10.45 Million | 0.00% | 0.45x | $2.10 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $118.88 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $1.07 Billion |
| Abeona Therapeutics Inc (ABEO) | $3.60 Million | -91.89% | 0.28x | $292.09 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $171.87 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $448.19K |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $345.85 Million |
| Arbutus Biopharma Corp (ABUS) | $88.00 Million | -44.09% | 0.34x | $840.56 Million |
| ABVC Biopharma Inc (ABVC) | $80.00K | -31.70% | 0.38x | $26.41 Million |
| Abivax SA American Depositary Shares (ABVX) | $40.58 Million | -434.26% | 4.06x | $9.33 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $23.36 Million | -97.44% | 0.37x | $3.74 Billion |
About Propanc Biopharma, Inc. Common Stock
Propanc Biopharma, Inc., a development-stage biopharmaceutical healthcare company, engages in the development of cancer treatments for patients with pancreatic, ovarian, and colorectal cancers in Australia. Its lead product candidate is PRP, an intravenous injection proenzyme treatment designed as a therapeutic option in cancer treatment and prevention which has completed pre-clinical studies. Th… Read more